SCHEMBL3866886

SCHEMBL3866886

O=C(Nc1ccccc1C(=O)Nc1n[nH]c2sc(C(=O)O)cc12)c1ccc(CN2CCCCC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 1/20 0.51
▸ BCR P11274 1/20 0.51
▸ HRH3 Q9Y5N1 3/20 0.47
▸ F10 P00742 2/20 0.46
▸ CYP2C9 P11712 1/20 0.44
▸ MAPT P10636 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ HDAC1 Q13547 6/20 0.42
▸ HDAC4 P56524 2/20 0.41
▸ HDAC3 O15379 1/20 0.41
▸ HDAC7 Q8WUI4 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ HDAC10 Q969S8 1/20 0.41
▸ HDAC11 Q96DB2 1/20 0.41
▸ HDAC8 Q9BY41 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ HDAC9 Q9UKV0 1/20 0.41
▸ HDAC5 Q9UQL6 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3866746 0.99 ABL1 (0.50) ABL1BCRHRH3F10CYP2C9
SCHEMBL3106720 0.92 ABL1 (0.53) ABL1BCRHRH3F10CYP2C9
SCHEMBL3085713 0.92 ABL1 (0.53) ABL1BCRHRH3F10CYP2C9
SCHEMBL3874968 0.92 MAPT (0.54) F10MAPTTSHRHDAC1KMT2A
SCHEMBL3104562 0.91 ABL1 (0.52) ABL1BCRHRH3F10CYP2C9
SCHEMBL3085794 0.90 ABL1 (0.50) ABL1BCRHRH3CYP2C9MAPT
SCHEMBL1779493 0.89 ABL1 (0.69) ABL1BCRHRH3F10CYP2C9
SCHEMBL1779462 0.88 ABL1 (0.68) ABL1BCRHRH3F10CYP2C9
SCHEMBL3866786 0.85 KDM4E (0.48) MAPTHDAC6MEN1KMT2AKDM4E
SCHEMBL3102260 0.84 KDR (0.53) ABL1BCRHDAC1HDAC6AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 — — EP disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 — — US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 — — EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 ABL1 397/4885BCR 1047/4885HRH3 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback